Clinical Trial Update: Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™ [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity study assessing antibody persistence and booster effects of the DTaP-HB-PRP~T combined vaccine (Tritanrix-HepB/Hib) developed by Sanofi P…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Disease
• Hepatitis B
• Pertussis
• Tetanus

Drugs mentioned

• DTaP-HB-PRP~T Combined Vaccine
• Tritanrix-HepB/Hib

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED | Results posted: 2013-11-21